TNFSF10 and metastatic neoplasm: Here, in an effort to maximize the therapeutic profile of MSC TRAIL, minimize off-target effects and accounting for metastatic disease, we originally developed a strategy where TRAIL is delivered by MSC that are also modified by an anti-GD2 chimeric antigen receptor (CAR) to target GD2-positive ES cells.